COMMUNIQUÉS West-GlobeNewswire

-
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
31/07/2025 -
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
31/07/2025 -
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
31/07/2025 -
Myriad Genetics Announces New $200 Million Credit Facility
31/07/2025 -
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
31/07/2025 -
InspireMD Announces Combined Financings of $58 Million
31/07/2025 -
Clover Health Applauds White House and CMS’ Push to “Tear Down Digital Walls,” Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians
31/07/2025 -
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
31/07/2025 -
NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
31/07/2025 -
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
31/07/2025 -
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
31/07/2025 -
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
31/07/2025 -
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
31/07/2025 -
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
31/07/2025 -
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
31/07/2025 -
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
31/07/2025 -
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025 -
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
31/07/2025 -
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
31/07/2025
Pages